# A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy

> **NCT02177071** · PHASE4 · COMPLETED · sponsor: **Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives** · enrollment: 211 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** INFLIXIMAB
- **DRUG:** AZATHIOPRINE
- **DRUG:** MERCAPTOPURINE
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT02177071
- **Lead sponsor:** Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-09
- **Primary completion:** 2021-06
- **Final completion:** 2021-10
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2022-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02177071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02177071, "A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02177071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*